CD28 antibody | YTH913.12
Filter by Application:F Reset
Rat anti Human CD28:StarBright Violet 670
- Product Type
- Monoclonal Antibody
|Rat anti Human CD28 antibody, clone YTH913.12 recognizes human CD28, a ~44 kDa single pass type 1 trans-membrane protein expressed as a homodimer on a major subset of human T-cells (Thompson et al. 1989), responsible for activation of these cells via interaction with the TCR. CD28 is involved in the tuning of the T-cell for activation via TCR, lowering the threshold for activation from around 8000 triggered TCRs to approximately 1500 (Viola et al.1996).
CD28 along with CD152, also known as CTLA-4 acts as a co-receptor for the co-stimulatory molecules CD80 and CD86 (Azuma et al. 1993). CD28 offers a positive stimulatory role on ligation of CD80 and CD86 while CTLA-4 offers a negative feedback signal preventing CD28 mediated T-cell activation of CD86 (Krummel et al. 1995).
Rat anti human CD28, clone YTH913.12 has been reported to recognize an epitope of CD28 expressed by NK cells, which is not recognized by other anti human CD28 clones such as 9.3 and CD28.2 (Galea-Lauri et al 1999.) Other reports however have failed to demonstrate CD28 staining on peripheral blood derived NK cells using clone YTH913.12 (
- Target Species
- Product Form
- Purified IgG conjugated to StarBright Violet 670 - liquid
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20
- Human peripheral blood T-cells
- Fusion Partners
- Spleen cells from an immunised DA rat were fused with cells of the Y3/Ag 1.2.3 rat myeloma cell line
- Max Ex/Em
Fluorophore Excitation Max (nm) Emission Max (nm) StarBright Violet 670 401 667
- For research purposes only
- 12 months from date of despatch
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
This product should be stored undiluted.
|Application Name||Verified||Min Dilution||Max Dilution|
- Flow Cytometry
- Use 5μl of the suggested working dilution to label 106 cells in 100μl. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
How to Use the SpectraviewerWatch the Tool Tutorial Video ▸
- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
References for CD28 antibody
Reiter, C. (1989) Cluster Report: CD28 in Leucocyte Typing IV: White Cell Differentiation Antigens. Edited by Knapp, W., Dorken, B., Gilks, W.R., Rieber, E.P., Schmidt, R.E., Stein, H. and von dem Borne, A.E.G.Kr.
Oxford University Press. pp 352-3.
McLeod, J.D. et al. (1998) Activation of human T cells with superantigen (staphylococcal enterotoxin B) and CD28 confers resistance to apoptosis via CD95.
J Immunol. 160: 2072-9.
Galea-Lauri, J. et al. (1999) Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells.
J Immunol. 163 (1): 62-70.
Wilson, J.L. et al. (1999) NK cell triggering by the human costimulatory molecules CD80 and CD86.
J Immunol. 163: 4207-12.
Costa, C. et al. (2002) Human NK cell-mediated cytotoxicity triggered by CD86 and Gal alpha 1,3-Gal is inhibited in genetically modified porcine cells.
J Immunol. 168: 3808-16.
Ponchel, F. et al. (2002) Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis.
Blood. 100: 4550-6.
Blanco, B. et al. (2003) Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells.
J Immunol. 171: 1070-7.
Goodier, M.R. and Londei, M. (2004) CD28 is not directly involved in the response of human CD3- CD56+ natural killer cells to lipopolysaccharide: a role for T cells.
Immunology. 111: 384-90.
View The Latest Product References
Gabdoulkhakova, A. et al. (2007) High rate of mutation reporter gene inactivation during human T cell proliferation.
Immunogenetics. 59: 135-43.
Kropf, P. et al. (2007) Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy.
Eur J Immunol. 37: 935-45.
Pridgeon, C. et al. (2011) Regulation of IL-17 in chronic inflammation in the human lung.
Clin Sci (Lond). 120: 515-24.
Litjens, N.H. et al. (2011) Identification of Circulating Human Antigen-Reactive CD4+FOXP3+ Natural Regulatory T Cells.
J Immunol. 188: 1083-90.
Svensson-Arvelund, J. et al. (2015) The human fetal placenta promotes tolerance against the semiallogeneic fetus by inducing regulatory T cells and homeostatic M2 macrophages.
J Immunol. 194 (4): 1534-44.
Hasib, L. et al. (2016) Functional and homeostatic defects of regulatory T cells in patients with coronary artery disease.
J Intern Med. 279 (1): 63-77.
Siska, E.K. et al. (2017) Generation of an immortalized mesenchymal stem cell line producing a secreted biosensor protein for glucose monitoring.
PLoS One. 12 (9): e0185498.
Hellberg, S. et al. (2021) Progesterone Dampens Immune Responses in In Vitro Activated CD4+ T Cells and Affects Genes Associated With Autoimmune Diseases That Improve During Pregnancy.
Front Immunol. 12: 672168.
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up